US Drug Recall Register

FDA Drug Recalls

17,898 recalls, newest first

Class II · Moderate risk Ongoing

Glycopyrrolate Tablets

Reason Failed Impurities/Degradation Specifications

Aurolife Pharma, LLC NDC 13107-014-01 D-0087-2023
Class II · Moderate risk Terminated

Rifampin Capsules USP

Reason Failed Impurities/Degradation Specifications: Failure observed in related substance testing during long term stability study.

Lupin Pharmaceuticals Inc. NDC 68180-659-06 D-0100-2023
Class II · Moderate risk Terminated

Menastil

Reason cGMP Deviations

Atlantic Management Resources Ltd. NDC 66233-711-01 D-0084-2023
Class II · Moderate risk Terminated

ProSirona

Reason cGMP Deviations

Atlantic Management Resources Ltd. NDC 66233-712-01 D-0083-2023
Class II · Moderate risk Terminated

Neuroquell

Reason cGMP Deviations

Atlantic Management Resources Ltd. D-0082-2023
Class II · Moderate risk Terminated

Neuroquell Plus

Reason cGMP Deviations

Atlantic Management Resources Ltd. D-0081-2023
Class II · Moderate risk Completed

Alcohol Antiseptic 80% Topical Solution Hand Sanitizer

Reason CGMP Deviations: Impurities of acetal and acetaldehyde were discovered in the product in excess of allowed limits.

NCH Life Sciences LLC NDC 55533-524-02 D-0092-2023
Class II · Moderate risk Terminated

Thiamine Hydrochloride 3000 mg/30 mL

Reason Presence of Particulate Matter: Presence of foreign substances were reported in vials at the pharmacy.

McGuff Compounding Pharmacy Services, Inc. D-0267-2023
Class II · Moderate risk Terminated

Thiamine Hydrochloride 200 mg/2mL

Reason Presence of Particulate Matter: Presence of foreign substances were reported in vials at the pharmacy.

McGuff Compounding Pharmacy Services, Inc. D-0266-2023
Class II · Moderate risk Terminated

Quinapril Tablets USP

Reason CGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.

Lupin Pharmaceuticals Inc. NDC 68180-558-09 D-0089-2023
Class II · Moderate risk Terminated

Quinapril Tablets USP

Reason CGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.

Lupin Pharmaceuticals Inc. NDC 68180-554-09 D-0088-2023
Class I · High risk Terminated

Advil Liqui Gels

Reason Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

Glaxosmithkline Consumer Healthcare Holdings DBA Haleon D-0183-2023
Class I · High risk Terminated

Advil Liqui Gels

Reason Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

Glaxosmithkline Consumer Healthcare Holdings DBA Haleon D-0182-2023
Class I · High risk Terminated

Advil

Reason Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

Glaxosmithkline Consumer Healthcare Holdings DBA Haleon D-0181-2023
Class III · Low risk Terminated

Lacosamide Oral Solution

Reason Failed Excipient Specifications: out of specification result observed for p-Hydroxybenzoic Acid content

Camber Pharmaceuticals, Inc NDC 31722-627-26 D-0094-2023
Class II · Moderate risk Terminated

Desmopressin Acetate Tablet

Reason Subpotent Drug: repackaged product was recalled by the manufacturer for subpotency.

RemedyRepack Inc. D-0077-2023
Class II · Moderate risk Completed

TUMS Antacid

Reason Presence of Foreign Substance: The foreign material is primarily comprised of glass mineral wool.

GlaxoSmithKline Consumer Healthcare Holdings LLC D-0079-2024
Class II · Moderate risk Completed

TUMS Antacid

Reason Presence of Foreign Substance: The foreign material is primarily comprised of glass mineral wool.

GlaxoSmithKline Consumer Healthcare Holdings LLC D-0078-2024